Ypsilanti, Michigan, USA (PRWEB) May 07, 2015
ISS is conducting two clinical investigational studies: (1) monitoring left-heart (left atrium or left ventricle) hemodynamics to improve the long-term treatment of congestive heart failure (CHF) patients, and (2) monitoring the left atrium to improve the safety and treatment of LVAD patients.
ISS’ Titan IHM implant has been designed to have significant clinical and technical advantages over the currently marketed implantable hemodynamic monitor, including its ability to monitor the left side of the heart. The main goal of tailored medication for CHF patients is to maintain a fine balance between improving cardiac output (blood flow pumped by a ventricle) and sustaining a reasonable left-heart filling pressure. Therefore, left-heart pressure waveforms are the most desirable parameters for the management of patients with cardiovascular problems, since unlike using pulmonary artery pressures, left filling pressure is not adversely affected by common pulmonary comorbidities such as pulmonary embolism. Monitoring the left heart is, however, very challenging due to the stringent biocompatibility and hemodynamic requirements of the left heart.
ISS is developing two categories of products: IHM sensors that are implanted adjunct to a planned thoracic surgery and implants that are delivered percutaneously via catheter-based techniques in either the pulmonary artery (PA) or left atrium during a stand-alone procedure. Titan IHM is composed of three components: a Telemetric Implant, a Monitoring Unit, and the Database Management system for internet-based worldwide access.
Dr. Nader Najafi, ISS President and CEO, stated that, “the early results of our first-in-human experiences are very promising. In addition to allowing optimized tailored medication for CHF patients, there have been many cases in which the Titan IHM product has assisted in both early identification and improved treatment of cardiac conditions such as different arrhythmias (atrial fibrillation, atrial flutter, supraventricular tachycardia, atrial tachycardia, etc.), mitral regurgitation, and tamponade. ”
Company Background: ISS is a leader in advanced MEMS technologies for design and manufacturing of industrial, medical, microfluidic and scientific analytical sensing applications. Founded in 1995, ISS is one of the oldest independent MEMS companies in the United States. ISS operates a comprehensive, state-of-the-art MEMS fabrication facility located near Ann Arbor, Michigan. ISS is currently certified for ISO 9001:2008, EN13980:2002 for its ATEX (intrinsically safe products), and ISO13485:2003 standard for Class III medical devices. ISS is a vertically integrated company dedicated to developing and manufacturing system-level products based on MEMS technology (MEMS Inside), please visit: http://www.mems-issys.com/
Source: Integrated Sensing Systems, Inc. (ISS)
Nader Najafi, Ph.D.
Integrated Sensing Systems Inc. (ISS)
391 Airport Industrial Dr., Ypsilanti, MI 48198
Tel: (734) 547-9896 Ext. 103
Fax: (734) 547-9964